Medytox

Medytox decided to invest 47.6 billion won in the construction of a new production line at its Osong 3rd plant E building. The investment period runs until August 25, 2020.

Medytox received regulatory approval from the Korean Ministry of Food and Drug Safety for its third production plant in Osong, North Chungcheong Province. The plant can produce 600 billion won worth of botulinum toxin products annually and is set to begin commercial production in June 2017.